Evercore ISI began coverage on shares of Axovant Sciences (NASDAQ:AXGT) in a research note published on Thursday, April 11th, Stock Target Advisor reports. The brokerage issued an outperform rating on the stock.
A number of other equities research analysts have also issued reports on the company. Zacks Investment Research raised Axovant Sciences from a hold rating to a buy rating and set a $1.25 target price on the stock in a research note on Wednesday, April 10th. HC Wainwright reaffirmed a buy rating and issued a $7.00 target price on shares of Axovant Sciences in a research note on Tuesday, March 12th. JMP Securities reissued an outperform rating and set a $6.00 price target (down previously from $8.00) on shares of Axovant Sciences in a research note on Monday, March 11th. Chardan Capital raised Axovant Sciences from a neutral rating to a buy rating and set a $4.00 price target on the stock in a research note on Monday, March 11th. Finally, Guggenheim initiated coverage on Axovant Sciences in a research note on Friday, February 15th. They set a buy rating and a $7.00 price target on the stock. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Axovant Sciences currently has a consensus rating of Buy and an average target price of $5.05.
AXGT opened at $1.13 on Thursday. The company has a quick ratio of 2.02, a current ratio of 2.02 and a debt-to-equity ratio of 1.24. The company has a market cap of $205.93 million, a price-to-earnings ratio of -0.55 and a beta of 1.23. Axovant Sciences has a 52 week low of $0.93 and a 52 week high of $6.59.
About Axovant Sciences
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.
Further Reading: Beta
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.